The recent approval of the dual-inhibitors (EGFR/HER2), such as lapatinib, opens a new avenue for therapeutic strategies with multitargeted drugs, not only directed against the surface receptors ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

While high expression of epidermal growth factor receptor (EGFR) has been considered an adverse ... As more women are found to have low HER2 expression breast cancer, they may benefit from the ...

Sunvozertinib inhibits EGFR and HER2, potentially leading to tumor regression and is being tested in first-line settings in the WU-KONG28 trial. Priority review aims for faster FDA action on drugs ...

BMBC is particularly common in breast cancers that are positive for epidermal growth factor receptor1 and 2 (EGFR and HER2), however, targeted therapies against BMBC, e.g., lapatinib - a EGFR/HER2 ...

The extracellular domain of HER2 is unable to bind extracellular ligands and depends on heterodimerization with other ligand-activated receptors like EGFR. 3 ...the combination of lapatinib plus ...

Please provide your email address to receive an email when new articles are posted on . Newer eGFR calculations that do not consider race show a link between kidney function and dementia.

Expert Rev Mol Diagn. 2008;8(4):417-434. Interestingly, cancers that co-overexpress EGFR and HER2 have a worse clinical outcome than those overexpressing either receptor alone. There is therefore ...

“While S1613 showed that anti-HER2 therapy was better tolerated and similarly efficacious to anti-EGFR therapy, the key finding is that the relative benefit of these therapies may depend on the ...